DP

Daewoong Pharmaceutical at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Daewoong Pharmaceutical brings 2 presentations to ObesityWeek 2026 in National Harbor. Its posters present new long-acting ways to deliver semaglutide, with first-in-human pharmacokinetics and safety data for a microneedle patch. A low-burst monthly depot shows sustained exposure in people and efficacy in obese rats.

OrganizationObesityWeek 2026 Attendance
DP
Daewoong Pharmaceutical
Seoul, South Korea
Large pharma
Drug maker developing long-acting forms of semaglutide, including a microneedle patch and a monthly depot.
Poster
Sat Nov 14
7:30pm–8:30pm
Low-Burst Monthly Semaglutide Depot Achieves Sustained Human Exposure and DIO Rat Efficacy
Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology
Poster
Sat Nov 14
7:30pm–8:30pm
Pharmacokinetics and Safety of a Semaglutide Microneedle Patch in a First-in-Human Study
Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Daewoong Pharmaceutical

Tell us what you sell and we’ll find the people at Daewoong Pharmaceutical most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction